Screener
UroGen Pharma URGN Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by UroGen Pharma in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: UroGen Pharma’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 8:05 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-025794
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Proceeds from issuance of long-term debt, net | 65,346 | — |
| Proceeds from pre-funded warrant issuance, net of issuance costs | — | 3 |
| Net cash provided by financing activities | 65,704 | 330 |
| Decrease in Cash and Cash Equivalents | (31,633) | (79,076) |
| Cash, Cash Equivalents and Restricted Cash at Beginning of Period | 112,095 | 173,062 |
| Cash, Cash Equivalents and Restricted Cash at End of Period | $80,462 | $93,986 |
| Supplemental Disclosures of Non-Cash Activities | ||
| Right-of-use assets obtained in exchange for new operating and finance lease liabilities | $338 | $3,358 |
Item 1. Financial Statements.
FAQ
- What is UroGen Pharma's net change in cash?
- UroGen Pharma (URGN) reported net change in cash of -$30.83M in Q2 2026.
- How has UroGen Pharma's net change in cash changed year-over-year?
- UroGen Pharma's net change in cash decreased by 177.2% year-over-year, from -$11.12M to -$30.83M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about UroGen Pharma's net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude